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CONCISE COMMUNICATION
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Mutations and Hepatitis B e Antigen Seroconversion in Patients
with Chronic Hepatitis B Virus
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Chee-Kin Hui,1 Danny Ka-Ho Wong,1
Joke Doutreloigne,2 Benjamin Chun-Yu Wong,1
Annie On-On Chan,1 and Ching-Lung Lai1
1Department of Medicine, University of Hong Kong, Queen
Mary Hospital, Hong Kong, People’s Republic
of China; 2Innogenetics, Ghent, Belgium
Chinese patients with chronic hepatitis B virus (332 with and 44 without cirrhosis-related
complications) were studied. Fifty percent of patients !30 years old had precore mutations.
The prevalence of precore mutations among hepatitis B e antigen (HBeAg)–positive patients,
although lower than that among anti-HBe–positive patients ( ), was already highPp .031
(44.2%). Median HBV DNA level in anti-HBe–positive patients was – cop-6 61.5 10 1.55 10
ies/mL, irrespective of the presence or absence of precore mutations. There was no difference
in the prevalence of precore mutations between patients with and without complications (P,
not significant). However the prevalence of core promoter mutations was higher among pa-
tients with complications than among those without complications (90.5% vs. 69.3%, respec-
tively; ). In conclusion, precore mutations occurred in a large proportion of ChinesePp .003
patients with chronic hepatitis B virus before HBeAg seroconversion. The development of
complications was not related to precore mutations but was probably due to the persistence
of significant viremia after HBeAg seroconversion.
It is believed that precore mutants emerge as a result of
selection under immune pressure during the process of hepatitis
B e antigen (HBeAg) seroconversion [1]. Precore mutants have
been detected in 4%–10% of HBeAg-positive patients [2, 3].
Some studies suggest that it is associated with more severe
hepatitis B virus (HBV) exacerbation and liver diseases [4, 5],
but this has not been confirmed elsewhere [1, 6].
Core promoter mutants of HBV decrease the precore mRNA
transcription while allowing the transcription of pregenomic
mRNA. In in vitro studies, core promoter mutants decrease
HBeAg production but enhance viral replication [7, 8]. How-
ever, in several in vivo studies, patients with core promoter
mutants have lower HBV DNA levels, compared with patients
without core promoter mutants [9, 10]. The core promoter mu-
tations are reported to be related with hepatocellular carcinoma
(HCC) [11, 12].
The primary objective of our study was to determine the
relationship between the development of precore and core pro-
moter mutants and HBeAg seroconversion, using an assay that
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is more sensitive than conventional sequencing for the detection
of the mutants. The secondary aim was to define the clinical
significance of these mutants.
Patients and Methods
In total, 376 Chinese patients with chronic HBV patients were
recruited from the Hepatitis Clinic, University of Hong Kong,
Queen Mary Hospital, Hong Kong, from January 1999 through
December 2001. Three hundred thirty-two patients had no bio-
chemical and clinical evidence of cirrhosis at presentation and sub-
sequent follow-up. Among the remaining 44 patients, 20 presented
with HCC and/or other cirrhosis-related complications, and 24 had
developed complications by subsequent follow-up. Among these
44 patients, 24 had HCC only, 8 had HCC and cirrhosis-related
complications, including ascites, encephalopathy, oesophageal var-
ice, or spontaneous bacterial peritonitis, and 12 had cirrhosis-re-
lated complications without HCC. HCC and other cirrhosis-related
complications are collectively referred to here as “complications.”
All patients were positive for hepatitis B surface antigen (HBsAg)
for at least 6 months. Serum was checked for HBeAg and antibody
to HBeAg (anti-HBe), liver biochemistry, HBV DNA levels (mea-
sured by the Digene Hybrid Capture II assay, Digene [lower limit
of detection, copies/mL]), and precore and core pro-60.14 10
moter mutations at the time of presentation and at the time of the
onset of complications for the 24 patients who developed compli-
cations during follow-up.
The precore and core promoter mutations of HBV were deter-
mined by use of an investigational research version of a line probe
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Table 1. Demographic data of patients with and without heptocellular carcinoma and/or cirrhosis-related complications.
Characteristic
Patients without complications (n p 332) Patients with complications (n p 44)
HBeAg (n p 131) Anti-HBe (n p 201) HBeAg (n p 16) Anti-HBe (n p 28)
Sex, M:F 88:43 152:49 13:3 19:9
Age, years 37 (18–82; 16) 45 (15–77; 15.5) 51 (32–80; 18.8) 61 (45–79; 13.5)
Follow-up, months 39 (8.9–184; 29.8) 42.9 (8.9–201; 50.4) 22 (13–135; 33.8) 34.4 (12.8–133; 45)
ALT level, U/L 42 (10–2010; 95) 61 (4–2660; 84.5) 65 (27–2040; 23.5) 65 (23–1270; 90.8)
HBV DNA level,  106 copies/mL 5.4 (!0.14–36,480; 245.4) 1.6 (!0.14–36,776; 11.5) 3.1 (!0.14–84.7; 20.4) 1.3 (!0.14–163; 7.1)
NOTE. Data are median (range; interquartile range [expressed here as the difference between the 25th and 75th centiles]), except for sex
ratio. ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.
assay (INNO-LiPA HBV Precore; Innogenetics). The line probe
assay contains specific probes covering the following motifs: (1)
core promoter nt 1762/1764 wild type (A/G), (2) core promoter nt
1762/1764 mutation (A/A), (3) core promoter nt 1762/1764 mu-
tation (A/T), (4) core promoter nt 1762/1764 mutation (T/A), (5)
precore codon 28 (nt 1896) wild type (TGG), and (6) precore codon
28 (nt 1896) mutation (TAG). The probes were applied on a ni-
trocellulose membrane. In brief, HBV DNA was amplified for the
core promoter/precore region using 5′ biotinylated primers [13].
After reverse hybridization of the biotinylated polymerase chain
reaction–fragments in the LiPA format, streptavidine–alkaline
phosphatase incubation and color development was used to identify
reactive probes. The presence of mixed population of wild-type and
mutant viruses was verified by clonal sequencing in 5% of the tested
serum to confirm the reactivity seen on the INNO-LiPA HBV Pre-
core assay.
Statistical analysis. The Mann-Whitney U test was used for
continuous variables, with skewed distribution and x2 test with
Yates’ correction factor or Fisher’s exact test used for categorical
variables. A general linear model was used to adjust confounding
factors.
Results
Demographic data and prevalence of precore and core promoter
mutations. The demographic data of the 332 patients without
complications and 44 patients with complications are shown in
table 1. Patients with complications had a significantly higher
median age than did patients without complications (58 years
[range, 32–80 years; interquartile range (IQR) (expressed here
as the difference between the 25th and 75th centiles), 15 years]
vs. 41 years [range, 15–82 years; IQR, 16 years], respectively;
). Among the 332 patients without complications, 322P ! .0001
and 313 patients had the results for precore and core promoter
regions, respectively, from the LiPA assay. Among the 44 pa-
tients with complications, 40 and 42 patients had the results
for precore and core promoter regions, respectively. The prev-
alence of precore and core promoter mutations stratified ac-
cording to HBeAg/anti-HBe status and alanine aminotransfer-
ase (ALT) levels are listed in table 2.
Relationship between the development of precore and core pro-
moter mutations and HBeAg seroconversion. The prevalence
of precore mutations in different age groups are as follows:
aged 10–30 years, 50%; aged 31–40 years, 48.9%; aged 41–50
years, 50%; aged 150 years, 58.1%. There were no significant
differences in the prevalence of precore mutations among the
different age groups. Though anti-HBe–positive patients had a
significantly higher prevalence of precore mutations (109/193
[56.5%]) than HBeAg-positive patients (57/129 [44.2%]; Pp
), the prevalence of precore mutations in HBeAg-positive.031
patients was already high.
Patients aged 10–30 years had a significantly lower prevalence
of core promoter mutations (52.2%), compared with those aged
31–40 years (71.5%; ), 41–50 years (77.3%; ),Pp .019 Pp .001
and 150 years (69.7%; ). There were no significant dif-Pp .001
ferences in the prevalence of core promoter mutations among the
latter 3 groups. There was no difference in the prevalence of core
promoter mutations between HBeAg-positive patients (85/123
[69.1%]) and anti–HBe–positive patients (132/190 [69.5%]).
ALT and HBV DNA levels in precore mutations. There were
no significant differences in the ALT and HBV DNA levels
between patients with and without precore mutations (median
ALT level, 59 U/L [range, 4–2660; IQR, 95] vs. 49 U/L [range,
13–1270; IQR, 77, respectively; ]; median HBV DNAPp .59
level, 6 copies/mL [range, –6 61.58 10 ! 0.14 10 36,776 10
copies/mL; IQR, 40.4 copies/mL] vs. 6 copies/mL1.99 10
[range, – 6; IQR, 6, respec-6! 0.14 10 36,080 10 26.19 10
tively; ]).Pp .53
For HBeAg-positive patients, there were no differences in
the ALT and HBV DNA levels for patients with and without
precore mutations (median ALT level, 44 U/L [range, 10–
2010 U/L; IQR, 203 U/L] vs. 42 U/L [range, 13–1220 U/L;
IQR, 50.25 U/L], respectively; ]; median HBV DNAPp .29
level, 6 copies/mL [range, 6– 65.44 10 ! 0.14 10 36,480 10
copies/mL; IQR, 6 copies/mL] vs. 6 cop-257.17 10 5.91 10
ies/mL [range, 6– 6 copies/mL; IQR,! 0.14 10 1313.14 10
6 copies/mL, respectively; ]).226.59 10 Pp .63
For anti-HBe–positive patients, there were again no differ-
ences in the ALT and HBV DNA levels for patients with and
without precore mutations (median ALT level, 64 U/L [range,
4–2660 U/L; IQR, 81.5 U/L] vs. 60 U/L [range, 16–1270 U/L;
IQR, 92 U/L, respectively; ]; median HBV DNA level,Pp .45
6 copies/mL [range, 6– 6 copies/1.50 10 ! 0.14 10 36,776 10
mL; IQR, 6 copies/mL] vs. 6 copies/mL18.38 10 1.55 10
[range, 6– 6 copies/mL; IQR, 6! 0.14 10 36,080 10 8.93 10
copies/mL, respectively; ]).Pp .75
ALT and HBV DNA levels in core promoter mutations.
Patients with core promoter mutations tended to have high-
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Table 2. Prevalence of precore and core promoter mutations stratified by hepatitis B e
antigen (HBeAg)/anti-HBe status and alanine aminotransferase (ALT) levels.
Promoter
mutation
HBeAg Anti-HBe
Patients without
complications
Patients with
complications
Patients without
complications
Patients with
complications
ALT  1
 ULN
ALT 1 1
 ULN
ALT  1
 ULN
ALT 1 1
 ULN
Precore
WT only 59.0 (46) 51.0 (26) 78.6 (11) 41.8 (33) 44.7 (51) 26.9 (7)
WT  MT 35.9 (28) 43.1 (22) 0.0 (0) 19.0 (15) 36.0 (41) 2.8 (1)
MT only 5.1 (4) 5.9 (3) 21.4 (3) 39.2 (31) 19.3 (22) 69.2 (18)
Core promoter
WT only 32.4 (24) 28.6 (14) 0.0 (0) 41.3 (33) 22.7 (25) 14.8 (4)
WT  MT 32.4 (24) 28.6 (14) 6.7 (1) 16.3 (13) 15.5 (17) 0.0 (0)
MT only 35.1 (26) 42.9 (21) 93.3 (14) 42.5 (34) 61.8 (68) 85.2 (23)
NOTE. Data are % (no.). For anti-HBe–positive patients with elevated ALT levels, the prevalence
of core promoter mutation (85/110) was higher than that of patients with normal ALT levels (47/80)
( ). There was no difference in the prevalence of precore mutations and core promoter mutationsPp .006
in any other groups. MT, mutant; ULN, upper limit of normal; WT, wild type.
er ALT levels and lower HBV DNA levels, compared with
those of patients without core promoter mutations (median
ALT level, 59 U/L [range, 4–1270 U/L; IQR, 89.5 U/L] vs.
46 U/L [range, 7–2460 U/L; IQR, 65.5 U/L, respectively;
]; median HBV DNA level, 6 copies/mLPp .066 1.7 10
[range, 6– 6 copies/mL; IQR, 6! 0.14 10 36,776 10 18.05 10
copies/mL] vs. 6 copies/mL [range, 6–2.43 10 ! 0.14 10
6 copies/mL; IQR, 6 copies/mL, respec-36,480 10 213.67 10
tively; ]).Pp .079
For HBeAg-positive patients, there was no difference in
the ALT levels between patients with and without core pro-
moter mutations (median ALT level, 43 U/L [range, 12–1220
U/L; IQR, 90 U/L] vs. 39.5 U/L [range, 12–2010 U/L; IQR,
129.5 U/L, respectively; ]). However, patients withPp .61
core promoter mutations had significantly lower HBV DNA
levels than did patients without core promoter mutations
(median HBV DNA level, 6 copies/mL [range,1.42 10
6– 6 copies/mL; IQR, 6 cop-! 0.14 10 36,472 10 124.26 10
ies/mL] vs. 6 copies/mL [range, 6–243 10 ! 0.14 10
6 copies/mL; IQR, 6 copies/mL, respec-36,480 10 575.92 10
tively; ]).Pp .004
For anti-HBe–positive patients, patients with core pro-
moter mutations had significantly higher ALT levels than did
patients without core promoter mutations (median ALT level,
65.5 U/L [range, 4–1270 U/L; IQR, 85 U/L] vs. 48.5 U/L
[range, 7–2460 U/L; IQR, 57.5 U/L, respectively; ]).Pp .032
However, the HBV DNA levels were comparable between
anti-HBe–positive patients with and without core promoter
mutations (median HBV DNA level, 6 copies/mL1.85 10
[range, 6– 6 copies/mL; IQR, 6! 0.14 10 36,776 10 11.29 10
copies/mL] vs. 6 copies/mL [range, 6–1.58 10 ! 0.14 10
6 copies/mL; IQR, 6 copies/mL, respec-711.7 10 24.23 10
tively; ]).Pp .86
Precore and core promoter mutations in patients with HCC
and/or cirrhosis-related complications. There was no differ-
ence in the prevalence of precore mutation between patients
with (22/40 [55%]) and without complications (166/322 [51.6%];
). Patients with complications had a significantlyPp .681
higher prevalence of core promoter mutations (38/42 [90.5%])
than patients without complications (217/313 [69.3%]; Pp
). Because some studies reported that core promoter mu-.003
tations were associated with the development of HCC [11, 12],
we compared the prevalence of core promoter mutations be-
tween patients with HCC and patients without HCC. There
was an increase in the prevalence of core promoter mutations
in HCC patients (27/31 [87.1%]), compared with patients with-
out HCC (217/313 [69.3%]; ), though this differencePp .039
became insignificant after adjusting for age ( ).Pp .269
Discussion
To our knowledge, this study was the first study to document
the occurrence of precore mutations in a high proportion of
patients from a very early age and before HBeAg seroconversion.
Other studies have reported a low incidence of precore mutations
(4%–10%) in HBeAg-positive patients [2, 3]. It has been suggested
that precore mutants are selected through immune pressure dur-
ing the process of HBeAg seroconversion. In this study, even
though the prevalence of precore mutations was higher in anti-
HBe–positive patients than in HBeAg-positive patients (Pp
), a large proportion of HBeAg-positive patients (44.2%).031
were already harboring precore mutants. This discrepancy was
most likely due to the methods used for the detection of the
precore mutations. We used the LiPA test, which can detect the
presence of 5%–10% of precore mutations in a mixed population
of wild-type virus and precore mutants [14]. However, this test
cannot quantify the exact proportion of wild-type virus and pre-
core mutants. The method commonly used in many other studies
is direct sequencing, with a sensitivity of detecting 30%–50% of
precore mutations in a mixed wild-type and precore viral pop-
ulation. This probably led to a gross underestimation of the prev-
alence of the precore mutations in the HBeAg-positive patients
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in previous studies. The more sensitive LiPA assay used in the
present study allowed a better approximation of the real prev-
alence of precore mutations in HBeAg-positive patients. Our
findings suggest that precore mutations develop early during the
phase of immune clearance of the hepatitis B virus, well before
actual HBeAg seroconversion. This was supported by the fact
that 50% of patients !30 years old already had precore mutations.
On the other hand, even after HBeAg seroconversion, 43.5%
(84/193) of our patients still had wild-type HBV alone (table
2), with a median HBV DNA level of copies/mL,61.55 10
which is comparable to patients with precore mutations.
The ALT and HBV DNA levels in our patients with and
without precore mutations were comparable, regardless of the
HBeAg or anti-HBe status. In addition, there was no difference
in the prevalence of precore mutations in patients with (22/40
[55%]) and without complications (166/322 [51.6%]; ).Pp .681
These findings suggest that precore mutations do not cause
more-severe disease.
Thus, in Chinese patients with chronic HBV infections, there
appears to be a spectrum of patients with wild-type virus alone,
precore mutants alone, and a mixed population of wild-type
virus and precore mutants both before and after HBeAg se-
roconversion. After HBeAg seroconversion, the median HBV
DNA level of our patients, although lower, was still 1106 copies/
mL, irrespective of the presence or absence of precore muta-
tions. The continuing development of cirrhosis and cirrhosis-
related complications after HBeAg seroconversion in Chinese
patients is probably related to this persistent viremia, but un-
related to the emergence of precore mutations.
Some studies show that core promoter mutations are asso-
ciated with the development of HCC [11, 12]. The present study
suggests that core promoter mutations were indeed associated
with the development of complications. However, the lack of
correlation between core promoter mutations and HCC after
age adjustment could reflect that some HCC may arise without
cirrhosis, possibly in a genotype-dependent manner [15]. The
role of HBV genotypes in hepatocarcinogenesis should be in-
vestigated in future studies.
In conclusion, to our knowledge this study was the first study
to show that precore mutations occurred early in chronic HBV
infection among the Chinese. The development of cirrhosis-
related complications and HCC was unrelated to precore mu-
tations, but was probably due to the persistence of significant
viremia after HBeAg seroconversion. Core promoter mutations
might also play a role.
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